サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1791471

抗体フラグメントの世界市場

Antibody Fragments

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.73円
抗体フラグメントの世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗体フラグメントの世界市場は2030年までに128億米ドルに達する見込み

2024年に92億米ドルと推定される抗体フラグメントの世界市場は、2024年から2030年にかけてCAGR 5.7%で成長し、2030年には128億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるモノクローナル抗体は、CAGR6.7%を記録し、分析期間終了時には77億米ドルに達すると予想されます。ポリクローナル抗体分野の成長率は、分析期間中CAGR 4.4%と推定されます。

米国市場は24億米ドルと推定、中国はCAGR 5.4％で成長すると予測

米国の抗体フラグメント市場は、2024年には24億米ドルになると推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.4%として、2030年までに20億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.2％と4.8％と予測されています。欧州では、ドイツがCAGR約4.5％で成長すると予測されています。

抗体フラグメント市場：主要動向と成長触媒の解明

抗体フラグメントがバイオ医薬品のゲームチェンジャーとなる理由とは？

抗体フラグメントは、完全長抗体よりも高い治療効果、高い組織浸透性、改善された安全性プロファイルを提供し、バイオ医薬品業界において革命的な力を発揮しています。従来のモノクローナル抗体とは異なり、これらのフラグメントは抗原結合部位を保持する一方でFc領域を排除しているため、免疫原性が低下し、腫瘍、炎症性疾患、神経疾患に対するより優れたターゲティングが可能となります。分子サイズが小さいためバイオアベイラビリティが向上し、迅速な分布と効率的な細胞内取り込みが重要な用途に最適です。より効果的で低コストの生物学的製剤に対する需要が高まる中、製薬会社は新規フラグメントベースの治療法を創出するための研究開発（R&D）に多額の投資を行っています。組換えDNA技術や合成生物学における最近の画期的な進歩は、市場の進化をさらに推し進め、抗体フラグメントを次世代治療薬に不可欠な要素として位置づけています。

市場力学は治療用途の増加からどのような影響を受けているか？

慢性疾患や自己免疫疾患の有病率の増加は、標的ドラッグデリバリーの進歩と相まって、抗体フラグメントの需要に拍車をかけています。これらの生物製剤は、免疫チェックポイント阻害や放射線免疫療法を強化する腫瘍学や、病原体のより正確で強力な中和を提供する感染症治療で支持を集めています。眼科領域、特に加齢黄斑変性（AMD）や糖尿病性網膜症の治療への応用も、市場の急拡大に寄与しています。さらに、二重特異性および三重特異性の抗体フラグメントの出現により、複数の疾患経路を同時に標的とすることが可能になり、新たな治療の道が開かれつつあります。大手製薬企業は戦略的提携を結び、これらの先進的バイオ治療薬の開発と競合市場化を加速させており、市場競争とイノベーションをさらに激化させています。

市場拡大における技術革新の役割とは？

抗体フラグメント作製技術の進化が市場を大きく形成しています。ファージディスプレイ、哺乳類細胞発現システム、細菌発酵の進歩により製造プロセスが合理化され、収率とコスト効率が向上しています。創薬における次世代シーケンシング（NGS）と人工知能（AI）の採用は、高親和性抗体フラグメントの迅速な同定と最適化を可能にし、新規治療薬の市場投入までの時間を短縮しています。さらに、吸入製剤や皮下製剤など非侵襲的な送達メカニズムへのシフトは、患者のコンプライアンスを高め、市場範囲を広げています。生物製剤に対する規制当局の支援と迅速な承認経路も、革新的な抗体フラグメントベースの治療の商業化を加速し、市場の見通しをさらに強めています。

市場成長を促進する主な要因は？

抗体フラグメント市場の成長は、標的生物製剤の採用の増加、免疫療法への研究開発投資の増加、バイオプロセス技術の進歩など、いくつかの要因によって牽引されています。個別化医療に対する需要の高まりは、特定の患者集団に合わせた抗体フラグメントの開発をさらに促進させています。さらに、開発・製造受託機関（CDMO）の拡大により、大規模生産が容易になり、コストが削減され、商業化が加速しています。合成生物学やタンパク質工学への関心の高まりは開発パイプラインを強化し、特異性が高く強力な治療薬の創出を可能にしています。一方、複雑な疾患の蔓延が増加していることと、新規生物製剤の承認を促す規制の枠組みが進化していることが、市場拡大の強力な原動力となっています。抗体フラグメント療法が優れた有効性、安全性、患者の利便性を実証し続けていることから、多様な治療領域でその採用が急増し、今後数年間の持続的な市場成長が見込まれます。

セグメント

特異性（モノクローナル抗体、ポリクローナル抗体）;アプリケーション（免疫不全アプリケーション、がんアプリケーション、その他のアプリケーション）

調査対象企業の例

  • AbbVie Inc.
  • Absolute Antibody Ltd
  • Amgen Oncology
  • AstraZeneca PLC
  • Axplora Group GmbH
  • Creative Biolabs
  • Jackson ImmunoResearch Inc.
  • Lonza Group AG
  • Sanofi SA
  • Sino Biological, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi Biologics
  • Xpress Biologics

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29180

Global Antibody Fragments Market to Reach US$12.8 Billion by 2030

The global market for Antibody Fragments estimated at US$9.2 Billion in the year 2024, is expected to reach US$12.8 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$7.7 Billion by the end of the analysis period. Growth in the Polyclonal Antibodies segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 5.4% CAGR

The Antibody Fragments market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.2% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Antibody Fragments Market: Unveiling Key Trends & Growth Catalysts

What Makes Antibody Fragments a Game-Changer in Biopharmaceuticals?

Antibody fragments are emerging as a revolutionary force in the biopharmaceutical landscape, offering enhanced therapeutic efficacy, greater tissue penetration, and improved safety profiles over full-length antibodies. Unlike conventional monoclonal antibodies, these fragments retain antigen-binding sites while eliminating the Fc region, reducing immunogenicity and enabling better targeting of tumors, inflammatory diseases, and neurological disorders. Their smaller molecular size enhances bioavailability, making them ideal for applications where rapid distribution and efficient cellular uptake are critical. With increasing demand for more effective, lower-cost biologics, pharmaceutical companies are investing heavily in research and development (R&D) to create novel fragment-based therapies. Recent breakthroughs in recombinant DNA technology and synthetic biology are further propelling the market’s evolution, positioning antibody fragments as an essential component in next-generation therapeutics.

How Are Market Dynamics Influenced by Rising Therapeutic Applications?

The increasing prevalence of chronic and autoimmune diseases, coupled with advancements in targeted drug delivery, is fueling the demand for antibody fragments. These biologics are gaining traction in oncology, where they enhance immune checkpoint inhibition and radioimmunotherapy, as well as in infectious disease treatment, where they provide more precise and potent neutralization of pathogens. Ophthalmic applications, particularly in the treatment of age-related macular degeneration (AMD) and diabetic retinopathy, have also contributed to a surge in market expansion. Furthermore, the emergence of bispecific and trispecific antibody fragments is creating new therapeutic avenues by enabling simultaneous targeting of multiple disease pathways. Major pharmaceutical players are forming strategic alliances to accelerate the development and commercialization of these advanced biotherapeutics, further intensifying market competition and innovation.

What Role Does Technological Innovation Play in Market Expansion?

The evolution of antibody fragment production technologies is significantly shaping the market. Advances in phage display, mammalian cell expression systems, and bacterial fermentation have streamlined the manufacturing process, leading to higher yields and cost-efficiency. The adoption of next-generation sequencing (NGS) and artificial intelligence (AI) in drug discovery has enabled faster identification and optimization of high-affinity antibody fragments, reducing the time to market for novel therapies. Additionally, the shift toward non-invasive delivery mechanisms, such as inhalable and subcutaneous formulations, is enhancing patient compliance and broadening the market reach. Regulatory support and expedited approval pathways for biologics are also accelerating the commercialization of innovative antibody fragment-based treatments, further strengthening market prospects.

What Are the Key Drivers Fueling Market Growth?

The growth in the antibody fragments market is driven by several factors, including the increasing adoption of targeted biologics, rising R&D investments in immunotherapy, and advancements in bioprocessing technologies. The surging demand for personalized medicine has further catalyzed the development of antibody fragments tailored to specific patient populations. Additionally, the expansion of contract development and manufacturing organizations (CDMOs) is facilitating large-scale production, reducing costs, and accelerating commercialization. Growing interest in synthetic biology and protein engineering is enhancing the development pipeline, allowing for the creation of highly specific and potent therapeutic agents. Meanwhile, the rising prevalence of complex diseases, combined with evolving regulatory frameworks that encourage the approval of novel biologics, is providing a strong impetus for market expansion. As antibody fragment therapies continue to demonstrate superior efficacy, safety, and patient convenience, their adoption is expected to surge across diverse therapeutic domains, driving sustained market growth in the years to come.

SCOPE OF STUDY:

The report analyzes the Antibody Fragments market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Specificity (Monoclonal Antibodies, Polyclonal Antibodies); Application (Immunodeficiency Application, Cancer Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • AbbVie Inc.
  • Absolute Antibody Ltd
  • Amgen Oncology
  • AstraZeneca PLC
  • Axplora Group GmbH
  • Creative Biolabs
  • Jackson ImmunoResearch Inc.
  • Lonza Group AG
  • Sanofi SA
  • Sino Biological, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi Biologics
  • Xpress Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Antibody Fragments - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Antibody Fragments in Targeted Cancer and Autoimmune Therapies
    • Growth in Next-Generation Antibody Engineering for Improved Efficacy
    • Expansion of Biopharmaceutical Applications for Single-Domain Antibodies (sdAbs)
    • Increasing Use of Antibody Fragments in Drug Delivery and Imaging Applications
    • Surge in Demand for Bispecific and Multispecific Antibody Fragments
    • Advancements in Phage Display Technology for Antibody Fragment Discovery
    • Increasing Investments in AI-Driven Antibody Fragment Development
    • Expansion of Contract Research and Manufacturing Services for Antibody Fragments
    • Growing Role of Antibody Fragments in Cell and Gene Therapy Applications
    • Rising Focus on Fully Human and Recombinant Antibody Fragments for Therapeutics
    • Surge in Demand for Antibody Fragments in Biosensors and Diagnostic Platforms
    • Increasing Strategic Partnerships for Rapid Commercialization of Antibody Fragments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antibody Fragments Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antibody Fragments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antibody Fragments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Antibody Fragments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Polyclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Polyclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Polyclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunodeficiency Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunodeficiency Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Immunodeficiency Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Antibody Fragments by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Antibody Fragments by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Antibody Fragments by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Rest of Europe 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Antibody Fragments Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Asia-Pacific 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Antibody Fragments by Specificity - Monoclonal Antibodies and Polyclonal Antibodies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of World 15-Year Perspective for Antibody Fragments by Specificity - Percentage Breakdown of Value Sales for Monoclonal Antibodies and Polyclonal Antibodies for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Antibody Fragments by Application - Immunodeficiency Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of World 15-Year Perspective for Antibody Fragments by Application - Percentage Breakdown of Value Sales for Immunodeficiency Application, Cancer Application and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION